Mesoblast Limited · ASX:MSB
Mesoblast — Shareholder Meeting (February 2011)
21 slides from Mesoblast's shareholder meeting presentation, Feb 9, 2011
Slide 1: Address by Mesoblast Chairman Brian Jamieson
For personal use only Address by Mesoblast Chairman Brian Jamieson Extraordinary General Meeting Mesoblast Limited Ladies and gentlemen, It is with great pleasure that the Board of Directors of Mesoblast Limited welcomes you to this important Extraordinary General Meeting. Having recently completed
Slide 2: Chairman's address conclusion and About Mesoblast
For personal use only On the other side, Cephalon has accessed exclusive commercial rights to market a number of Mesoblast’s valuable products, and has acquired a significant holding and ownership stake in Mesoblast, emphasizing the company’s belief in the value of the entire range of product servin
Slide 3: Leading the world in novel adult stem cell therapies
For personal use only Leading the world in novel adult stem cell therapies Extraordinary General Meeting 9 February 2011
Slide 4: Safe Harbor Statement
Safe Harbor Statement For personal use only This announcement may contain forward-looking statements made pursuant to the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this presentation regarding potential applications
Slide 5: Investment snapshot
Investment snapshot Current Post EGM¶ For personal use only Issued shares 254m 279m ¶ Additional Cephalon investment and Current share price $5.65 balance of upfront payment is subject to approval at 9 February 2011 EGM. Cash available (approx)¶ A$140m A$280m Market cap A$1,435m A$1,575m Capital rai
Slide 6: Cephalon strategic alliance
Cephalon strategic alliance Cephalon receives exclusive worldwide commercialization rights to selected For personal use only Mesoblast products alliance to focus on degenerative conditions of cardiovascular and neurologic systems, and bone marrow transplantation Mesoblast to receive upfront fe
Slide 7: The Mesoblast value proposition – the three pillars
The Mesoblast value proposition – the three pillars For personal use only 1. The Cephalon alliance delivers proven execution capability in major global markets drives clinical programs in key therapeutic areas – experienced team cash from milestone payments to fund Mesoblast pipeline 2. Intrav
Slide 8: The foundation – our proprietary adult stem cells
The foundation – our proprietary adult stem cells For personal use only potent, purified adult mesenchymal precursor cells – strong safety profile – no immune reactions – avoid ethical and safety issues associated with embryonic stem cells – backed by strong patent position “off the shelf” – jus
Slide 9: We own the intellectual property on Mesenchymal Precursor Cells (MPC)
We own the intellectual property on Mesenchymal Precursor Cells (MPC) For personal use only Heart muscle Products for Bone marrow + cardiovascular antibody diseases Blood vessels Magnetic beads Pancreas Products for diabetes & MPC highly-expandable + immunologic/ Magnet Immune non-immunogenic inflam
Slide 10: Our industrial scale manufacturing process
Our industrial scale manufacturing process Bone marrow from universal donor For personal use only BM + stem cell-binding antibody homogeneous cell population Magnetic beads well-controlled cell expansion efficient large-scale expansion Magnet lower costs of cell culture process Fresh, quiesc
Slide 11: Manufacturing strategy is central to maximising value
Manufacturing strategy is central to maximising value For personal use only 1. State-of-the-art manufacturing plant via strategic alliance cost neutral tax effective geographical location best of breed, cutting edge technology 2. Retain control of manufacture for all products product delinea
Slide 12: "Off-the-shelf" product portfolio driving value creation
“Off-the-shelf” product portfolio driving value creation IND FDA For personal use only clearance approval Lead products Pre-clinical Phase I Phase II Phase III Congestive heart failure Bone marrow transplantation Spinal fusion Knee osteoarthritis Long bone fracture repair Acute myocardial infarction
Slide 13: Key indications – US markets
Key indications – US markets 1 . Cardiovascular diseases For personal use only congestive heart failure (CHF) – 6.2 million in US alone, > 670,000 new patients annually acute myocardial infarction (AMI) – 1.2 million new patients annually 2. Bone marrow transplantation, expansion of umbilical co
Slide 14: Other target US markets
Other target US markets For personal use only 5. Intervertebral disc repair/regeneration > 4 million patients affected 6. Knee osteoarthritis > 15 million patients affected 7. Spinal fusion > 500,000 procedures each year 8. Repair of non-union long bone fractures 5-10% of all long bone fract
Slide 15: "Off the shelf" cells in congestive heart failure (CHF)
“Off the shelf” cells in congestive heart failure (CHF) 60 patient multi-center, randomized, controlled Phase 2 trial For personal use only Class II-IV CHF, ejection fraction < 40% (high 6- and 12-month mortality) randomized 3:1 controls to MPCs at 25M, 75M or 150M cell doses cells injected
Slide 16: MPC treated patients have fewer cardiac-related events, hospitalizations, and deaths
MPC treated patients have fewer cardiac-related events, hospitalizations, and deaths than controls For personal use only Event MPC treatment (N=45) Controls (N=15) p value No. patients with event (%) No. patients with event (%) Any Serious Adverse Cardiac 20 (44.4%) 14 (93.3%) 0.001 Event (SAE) Repe
Slide 17: MPC treatment lowers rate of Serious Adverse Cardiac Events over time
MPC treatment lowers rate of Serious Adverse Cardiac Events over time 0.06 Event Rate Cardiac Serious Adverse Event Per Month 0.05 For personal use only Subject Follw-Up 0.04 54% reduction, p=0.03 0.03 0.02 0.01 0 Control (n=15) MPCs (n=45) 0.06 Event Rate Cardiac Serious 0.05 Adverse Event Per Mont
Slide 18: MPC treatment lowers rate of Major Adverse Cardiac Events over time
MPC treatment lowers rate of Major Adverse Cardiac Events (MACE*) over time 0.025 MACE Event Rate Per Month 0.02 For personal use only Subject Follow-Up 0.015 84% reduction, p=0.01 0.01 0.005 0 Control (n=15) MPCs (n=45) 0.025 0.02 MACE Event Rate Per Month Subject Follow-Up 0.015 0.01 0.005 0 Contr
Slide 19: MPC treatment lowers rate of cardiac-related and heart failure hospitalizations
MPC treatment lowers rate of all cardiac-related and heart failure hospitalizations over time 0.06 For personal use only 0.05 48% reduction in rate of all Cardiac Hospitalization Event Rate Per Month Subject Follow-Up 0.04 cardiac hospitalizations (p=0.07) 0.03 0.02 0.01 0 Control (n=15) MPCs (n=45)
Slide 20: Value inflexion points – near term
Value inflexion points – near term For personal use only commencement of Phase 3 cord blood expansion trial for FDA approval successful completion of Phase 2 heart failure trial – progression to Phase 3 pivotal trial commencement of intra-coronary heart attack Phase 2 trial successful comple
Slide 21: Leading the world in novel adult stem cell therapies
For personal use only Leading the world in novel adult stem cell therapies